The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

A Generic Version of Intuniv Will Be Launched In December 2014

Actavis, Inc., a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with Shire plc resolving outstanding patent litigation related to Actavis' gener...

Actavis resolves Intuniv patent litigation with Shire

Actavis has resolved outstanding patent litigation concerning generic version of Intuniv (guanfacine hydrochloride), indicated for the treatment of attention deficit hyperactivity disorder, with Shire...

Shire settles with ActavisWatson over Intuniv; Lilly sues J&J

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE: ACT) and Watson Laboratories (which acquired Actavis and is now also trading under that name) for...

Shire settles Intuniv lawsuits with TWi, Anchen

Irish drugmaker Shire PLC said Thursday it settled a lawsuit over the patents on its attention deficit hyperactivity drug Intuniv, and will allow another company to make a generic version in 2016.Shi...

SHIRE PLC - Shire Settles INTUNIV Litigation with Actavis and Watson

Shire Settles All Pending Litigation with Actavis and Watson concerning INTUNIV ® Philadelphia, PA, United States - April 25, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG), announces that its subsidia...

Shire move delays Intuniv generic until 2014

Shire move delays Intuniv generic until 2014

BRIEF-Shire settles Intuniv litigation with Anchen

LONDON, Sept 6 (Reuters) - Shire PLC : * Shire settles all pending intuniv litigation with anchen * Settlement provides twi pharma with license to make,anchen license to market,

Actavis resolves patent litigation related to generic version of INTUNIV for treatment of ADHD

Actavis, Inc., a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with Shire plc resolving outstanding patent litigation related to Actavis' generic...

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release.

BACKGROUND: α2-Adrenoceptor agonists are used adjunctively to psychostimulants in treating attention-deficit/hyperactivity disorder (ADHD) when psychostimulants alone do not sufficiently reduce sympt...

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate.

BACKGROUND: In clinical practice, α2-adrenoceptor agonists have been adjunctively administered with psychostimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD). Two studies...

Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.

Objective: To evaluate the efficacy and safety of guanfacine extended release (XR, Intuniv; Shire Development Inc., Wayne, PA, USA) in the treatment of oppositional symptoms in children aged 6-12 year...